Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 3/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.56 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.56 |
| ▸ | HCAR1 | Q9BXC0 | 4/20 | 0.51 |
| ▸ | CLK1 | P49759 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2195887 | 1.00 | CDK9 (0.56) | CDK9DYRK1ADYRK2HCAR1CLK1 | |
| SCHEMBL2192711 | 0.82 | HCAR1 (0.51) | CDK9DYRK1ADYRK2HCAR1GAA | |
| SCHEMBL2193920 | 0.82 | HCAR1 (0.51) | CDK9DYRK1ADYRK2HCAR1CLK1 | |
| SCHEMBL20508463 | 0.74 | DYRK1A (0.97) | CDK9DYRK1ADYRK2CLK1ALDH1A1 | |
| SCHEMBL21391122 | 0.74 | CDK9 (0.51) | CDK9DYRK1ADYRK2HCAR1CLK1 | |
| SCHEMBL20508457 | 0.73 | DYRK1A (0.56) | CDK9DYRK1ADYRK2HCAR1CLK1 | |
| SCHEMBL20508660 | 0.72 | DYRK1A (1.00) | CDK9DYRK1ADYRK2CLK1ALDH1A1 | |
| SCHEMBL2195668 | 0.71 | HCAR1 (0.48) | HCAR1GAAALDH1A1AURKAJAK2 | |
| SCHEMBL2193662 | 0.71 | HCAR1 (0.48) | HCAR1GAAALDH1A1AURKAJAK2 | |
| SCHEMBL2195177 | 0.71 | HCAR1 (0.48) | HCAR1GAAALDH1A1AURKAJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507473-B2 | 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders | ARENA PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | claimed |
| US-20110172209-A1 | 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | claimed |
| US-8507473-B2 | 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders | ARENA PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507473-B2 | 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders | ARENA PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507473-B2 | 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders | ARENA PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20110172209-A1 | 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172209-A1 | 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172209-A1 | 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| WO-2010030360-A1 | 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172209-A1 | 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS | GPR84, GPR119, GPR65 | CDK9 1895/4885DYRK1A 2913/4885DYRK2 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.